← Back to patent-cliff list
Zorevunersen
Tier C — Watch / tradeZorevunersen
Stoke Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：Nav1.1
Indications (approved)：Dravet syndrome
Regional status
US
Phase III
2025-06-04
EU
Phase III
2025-06-04
China
Phase III
2025-06-04
Japan
Phase III
2025-06-04
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Zorevunersen?
Approved indications include: Dravet syndrome.
When does the Zorevunersen patent expire?
No public expiry year is available for Zorevunersen yet; this page updates once verified.
How do I get a quote for Zorevunersen intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30